P R I X G A L I E N U S A 2 0 2 4 | W I N N E R Best Pharmaceutical Product PAXLOVID(TM) — Pfizer Inc. Watch the ceremony: Mike Rosenblatt announces Best Pharma (9:26) SUBMISSION OVERVIEW Category Best Pharmaceutical Product Company Pfizer Inc. Product /...
More
P R I X G A L I E N U S A 2 0 2 4 | W I N N E R Best Pharmaceutical Product PAXLOVID(TM) — Pfizer Inc. Watch the ceremony: Mike Rosenblatt announces Best Pharma (9:26) SUBMISSION OVERVIEW Category Best Pharmaceutical Product Company Pfizer Inc. Product / Technology PAXLOVID(TM) Trade Name PAXLOVID(TM) Date of Approval 2023-05-25 Therapeutic Areas Infectious Disease, anti-virals Subcategory Biotechnology Employees 1-10 INDICATIONS Treatment of mild-to-moderate COVID-19 in adults who are at high risk of progression to severe COVID-19, including hospitalization or death. BACKGROUND PAXLOVID (nirmatrelvir/ritonavir) has been developed to meet an unmet clinical need in the treatment of COVID-19 disease caused by SARS-CoV-2 infection. Due to its contagious nature, severity, and impact on healthcare systems, particularly intensive care units, COVID-19 is a major public health challenge of worldwide significance. SARS-CoV-2 is a highly infectious, ribonucleic acid (RNA) beta coronavirus that c
Less
